UNSPSC 51172303: Dimercaprol

This classification denotes a metal chelator with the molecular formula C3H8OS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0CPP32S55X, chemically known as 2,3-mercaptopropanol but generally known as dimercaprol, which bears US NIH Compound Identifier 3080. European Medicines Agency schedules Dimercaprol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07165MIG. The term DIMERCAPROL is an International Non-Proprietary Name.

UNSPSC 51172303 Dimercaprol, a Commodity code, represents pharmaceutical products and related testing services procured by state and local health, justice, and human services agencies. Recent solicitations show state and local governments buying drug testing services, generic pharmaceuticals for distribution through state health systems, and pharmacy benefit program capabilities. The mix of issuing bodies includes county criminal justice departments (Collin County Community Supervision and Corrections Department), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances administered by state procurement offices (Minnesota Department of Administration). The code's apparent breadth—spanning offender drug screening, direct-to-manufacturer prescription programs, and generic pharmaceutical contracting—reflects how state and local procurement offices tag diverse pharmaceutical and testing-related services under related commodity codes.

Geographic activity is concentrated in Texas and Minnesota, with multistate reach through cooperative vehicles. Collin County (Texas) issued RFP 2026-327 on July 9, 2026, soliciting offender specimen collection and drug testing services with a response deadline of July 23, 2026 and an estimated contract value of $600,000 over two years with three optional one-year renewals; the scope includes staffing collection sites in Plano and McKinney, immunoassay screening with LC/MS/MS or GC/MS confirmation, and alternative testing methodologies (oral fluid and hair), with evaluation weighted toward vendor understanding (30 points), firm qualifications (25 points), client references (15 points), and cost (30 points). The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, gathering market intelligence on direct-to-manufacturer prescription programs without formal competitive timelines or award values. The Minnesota Department of Administration, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers to state and local government facilities in Minnesota and Oregon, with evaluation weighted 75 percent on price competitiveness and 25 percent on compliance, EDI capability, and administrative fee structure.